Accelerating Pediatric Oncology Prior Authorizations with Da Vinci PAS

Klivira's platform automates prior authorizations for pediatric oncology, leveraging Da Vinci PAS to standardize and expedite approvals for life-saving treatments.

Revenue cycle directors and prior authorization coordinators in pediatric oncology face unique challenges, balancing urgent clinical needs with complex payer requirements. The integration of HL7 Da Vinci Project standards offers a path to reduce administrative burden and accelerate access to critical therapies for childhood cancer patients.

The Unique Prior Authorization Landscape in Pediatric Oncology

Pediatric oncology treatments often involve high-cost, complex therapies with stringent prior authorization requirements. These include advanced chemotherapy regimens, cutting-edge CAR-T cell therapies, and specialized radiation like proton beam therapy. The administrative overhead and potential for delays in securing prior authorizations for these critical services can directly impact patient care timelines.

Challenges with Traditional Prior Authorization Workflows in Pediatric Oncology

**Per-payer custom integration:** Each payer portal or fax submission requires unique processes, leading to fragmented workflows and increased manual effort for pediatric oncology teams.
**Unstructured clinical attachments:** Clinical documentation, such as detailed chemotherapy protocols or CAR-T eligibility criteria, is often submitted as PDFs, hindering automated payer review.
**Slow decision turnaround:** The manual parsing of unstructured documentation by payer-side reviewers can delay approvals for time-sensitive pediatric cancer treatments.
**Inconsistent response semantics:** Varying approval, denial, and pending statuses across payers create confusion and additional work for PA coordinators tracking childhood cancer cases.

Transforming Pediatric Oncology PA with Da Vinci PAS

Klivira's Da Vinci PAS-conformant implementation standardizes the prior authorization process, moving away from disparate systems to a unified FHIR-based workflow. This approach is particularly impactful for pediatric oncology, where the need for rapid, accurate authorizations is paramount for treatments guided by COG protocols or NCCN guidelines.

Klivira's Da Vinci PAS Workflow for Pediatric Oncology

**Pre-PA coverage discovery via Da Vinci CRD:** At order entry for chemotherapy or CAR-T, Klivira integrates with the EMR via CDS Hooks to surface payer coverage requirements, informing clinical decisions upfront.
**Documentation assembly via Da Vinci DTR:** For complex cases, DTR questionnaires guide the collection of structured clinical documentation, such as detailed treatment plans or imaging results, populated directly from EMR FHIR data.
**PAS submission:** Klivira submits the assembled FHIR bundle to the payer's PAS endpoint, including structured clinical documentation as `DocumentReference` and related FHIR resources for treatments like proton beam therapy.
**Synchronous or asynchronous response:** The payer's PAS endpoint returns a `ClaimResponse` resource, which Klivira parses into a consistent workflow state, providing clarity on approval, denial, or pending status.
**Status tracking:** Klivira continuously monitors decision states through PAS inquiry operations or webhook events, ensuring pediatric oncology teams have real-time updates.
**Response back into the EMR:** The authorization number, decision text, and any conditions are written back to the EMR's order record, streamlining the integration of PA decisions into the patient's chart.

Navigating Payer Conformance and Regulatory Mandates for Childhood Cancer Care

The regulatory landscape, particularly CMS-0057-F, mandates FHIR-based Prior Authorization APIs for impacted payers by January 1, 2027. Klivira's platform tracks per-payer conformance status and ensures seamless operation whether a payer is fully Da Vinci PAS-conformant or requires fallback to X12 278/275 or portal submissions. This adaptability is crucial for maintaining continuity of care in pediatric oncology as payers transition.

Klivira's Da Vinci PAS Implementation for Pediatric Oncology

Klivira's prior authorization automation platform delivers a comprehensive Da Vinci PAS solution tailored for the specific demands of pediatric oncology. Our system constructs `Claim` resources per the PAS IG, leverages DTR for structured documentation assembly, and integrates CRD at the EMR order entry point. For payers not yet fully PAS-conformant, Klivira intelligently routes submissions via X12 278 or existing provider portals, ensuring no treatment is delayed due to varied payer readiness.

Frequently asked questions

How does Da Vinci PAS improve turnaround times for pediatric oncology treatments?

By enabling the submission of structured clinical documentation via FHIR, Da Vinci PAS allows payers to potentially automate more of their review process. This reduces the manual effort and parsing time associated with unstructured documents, leading to faster decision turnaround times for critical pediatric oncology therapies.

What types of pediatric oncology treatments benefit most from Da Vinci PAS integration?

High-cost, complex treatments such as chemotherapy regimens, CAR-T cell therapies, and advanced imaging or radiation services like proton beam therapy benefit significantly. The structured data exchange facilitated by Da Vinci PAS ensures that the detailed clinical evidence required for these authorizations is presented efficiently to payers.

Does Klivira's solution handle both PAS-conformant and non-PAS payers for pediatric oncology?

Yes, Klivira's platform is designed to intelligently route prior authorization requests. For payers that are Da Vinci PAS-conformant, we use the FHIR-based workflow. For payers not yet supporting PAS, Klivira seamlessly falls back to traditional X12 278 EDI transactions, payer portals, or fax, ensuring comprehensive coverage for all pediatric oncology prior authorizations.

How does structured clinical documentation in Da Vinci PAS impact complex pediatric oncology cases like CAR-T?

For complex cases such as CAR-T, Da Vinci PAS, especially with Da Vinci DTR, ensures that all necessary clinical criteria and documentation are collected in a structured, machine-readable format. This clarity reduces ambiguity for payer reviewers and helps to expedite the clinical necessity review process, which is vital for time-sensitive cellular therapies.

How does Klivira ensure compliance with CMS-0057-F for pediatric oncology prior authorizations?

Klivira actively tracks the implementation status of payers under CMS-0057-F, which mandates FHIR-based PA APIs. Our platform is built to align with these requirements, enabling pediatric oncology providers to meet the new standards for impacted payers and leverage the associated benefits, such as expedited decision timeframes for urgent requests.